Search
Returning search results with filters:
Remove filter for
Audience: Healthcare
Remove filter for
Category: Drugs
Remove filter for
Issue: Product safety
Remove filter for
Type: Alert
Clear all
Search filters
Type
Audience
Category
Issue
Last updated
Displaying 1 - 15 of 59 items.
Importation of Italian-authorized Cisatracurio Hikma 2 mg/mL Ampoules due to the Current Shortage of Canadian-authorized Cisatracurium Omega
AlertHealth professional risk communication | 2024-04-24
Ezetrol (ezetimibe) and the Risks of Drug-Induced Liver Injury and Severe Cutaneous Adverse Reactions
AlertHealth professional risk communication | 2024-03-27
Importation of UK-Authorized Potassium Chloride 15% w/v Concentrate for Solution for Infusion due to shortage of Canadian-authorized Potassium Chloride for Injection Concentrate
AlertHealth professional risk communication | 2023-10-24
Janus Kinase Inhibitors and the Risk of Major Adverse Cardiovascular Events, Thrombosis (Including Fatal Events) and Malignancy
AlertHealth professional risk communication | 2022-10-31
IMBRUVICA (ibrutinib) - Risk of Serious and Fatal Cardiac Arrhythmias or Cardiac Failure
AlertHealth professional risk communication | 2022-08-29
Recall of one lot of pms-Hydromorphone due to packaging error that could potentially lead to overdose
AlertPublic advisory | 2022-08-20
Sodium Acetate Injection, USP - Potential for the Presence of Particulate Matter
AlertHealth professional risk communication | 2022-03-15
0.9% Sodium Chloride Injection, USP and Lactated Ringer’s Injection, USP - Potential Leak During Pressure Infusion
AlertHealth professional risk communication | 2022-03-09
Distribution of NUVAXOVID with English-only Vial and Carton Labels
AlertHealth professional risk communication | 2022-02-23
BEOVU (brolucizumab) – Risk of Intraocular Inflammation, Retinal Vasculitis and/or Retinal Vascular Occlusion
AlertHealth professional risk communication | 2022-02-03
XELJANZ/XELJANZ XR (tofacitinib) – Risk of Major Adverse Cardiovascular Events, Malignancy, Thrombosis and Infection
AlertHealth professional risk communication | 2022-01-12
Authorization of Casirivimab and Imdevimab with English-only Labels for Use in Relation to the COVID-19 Pandemic
AlertHealth professional risk communication | 2021-07-30
CHAMPIX (varenicline) — Potential Risk Posed by Long-Term Exposure to Nitrosamine Impurity, N-nitrosovarenicline, Exceeding Acceptable Intake Limit
AlertHealth professional risk communication | 2021-06-30
GILENYA (fingolimod) - Risk of Liver Injury
AlertHealth professional risk communication | 2021-01-18